Clinical trial
Leflunomide in Treating Patients With Anaplastic Astrocytoma in First Relapse
NCT00003775 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00003775 |
|---|---|
| Title | Leflunomide in Treating Patients With Anaplastic Astrocytoma in First Relapse |
| Official title | A Phase II Open Label Study of SU101 for Patients With Anaplastic Astrocytoma in First Relapse |
| Lead sponsor | Pfizer, Industry |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors |
| Intervention type | Drug |
| Interventions | leflunomide |
| Enrollment | 60 |
| Start date | Dec 1, 1998 |
| Primary completion | May 1, 2006 |
| Completion | May 1, 2006 |
| First posted | Sep 14, 2004 |
| Last update posted | Sep 13, 2012 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: